Program Schedule

1037
The risk factors for resistant Esherichia coli infections after prostate biopsy under fluoroquinolone prophylaxis

Session: Poster Abstract Session: UTIs: Epidemiology and Diagnostic Testing
Friday, October 10, 2014
Room: The Pennsylvania Convention Center: IDExpo Hall BC
Posters
  • abstract-44609.jpg (938.1 kB)
  • Background:

    To evaluate the risk factors of fluoroquinolone resistant or ESBL-producing E coli infections after prostate biopsy under flouroquinolone prophylaxis

    Methods:

    From January 2003 to December 2012, we evaluated the records of 2215 patients who underwent TRUS guided 12-core prostate biopsy under flouroquinolone prophylaxis. The risk factors including age, diabetes mellitus, hypertension, history of hospital admission within 30 days, prior use of quinolons within 6 months of the biopsy, first or repeat biopsy  were evaluated  for the development of flouroquinolon resistance and ESBL producing E coli

    Results:

    Of the 2215 patients, 153  had positive urine cultures such as 129 (84.3%) E coli, 8 (5.2%) Enterococcus spp, 6 (3.9%) Enterobacter spp, 5 (3.2%)  Pseudomonas spp, 3 (1.9%) MRCNS, 2 (1.3%)  Klebsiella spp. Of the positive urine cultures yielded E coli, 99 (76.7%) were evaluated for fluoroquinolone (ciprofloxacin) resistance. In these group 83 (83.8%) were fluoroquinolone resistant. In addition to 129 E coli strains were examined for ESBL producing and ESBL positivity was found in 67 (51,9%) of these strains. When the risk factors regarding the infection caused by ESBL producing or quinolon resistant E coli strains were examined, the use of quinolones in the last 6 months and a history of hospitalization in the last 30 days were found to be significant (p=0,00, p=0,021 and p=0,034, p=0,041 respectively)

    Conclusion:

    We found that while fluoroquinolone prophylaxis started before TRUS-guided prostate biopsy is still effective in preventing infectious complications that might develop after biopsy, fluoroquinolone-resistant or ESBL-producing E coli strains might be a common microorganism in patients with this kind of complication. This study examined various risk factors for the development of infection in both ESBL-producing strains and strains that developed resistance to fluoroquinolones. Among these factors, a history of the use of fluoroquinolones in the last 6 months and hospitalization in the last one month were found to be significant.

    Özlem Kandemir, Professor1, Murat Bozlu2, Ozan Efesoy2, Onur Gültekin1 and Erdem Akbay2, (1)Clinical Microbiology and Infectious Diseases, Mersin University School of Medicine, Mersin, Turkey, (2)Urology, Mersin University School of Medicine, Mersin, Turkey

    Disclosures:

    Kandemir, None

    M. Bozlu, None

    O. Efesoy, None

    O. Gültekin, None

    E. Akbay, None

    << Previous Abstract | Next Abstract

    Findings in the abstracts are embargoed until 12:01 a.m. EDT, Oct. 8th with the exception of research findings presented at the IDWeek press conferences.

    Sponsoring Societies:

    © 2014, idweek.org. All Rights Reserved.

    Follow IDWeek